IDO1 and glioblastoma: Aberrant tryptophan metabolism has been identified as an important metabolic node and immune checkpoint in glioblastoma, and several studies have discovered that targeting this pathway’s rate-limiting enzyme indoleamine 2,3-dioxygenase 1 can enhance therapeutic effect by mitigating immunosuppression62–64.